1. Home
  2. GNPX vs AMBO Comparison

GNPX vs AMBO Comparison

Compare GNPX & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • AMBO
  • Stock Information
  • Founded
  • GNPX 2009
  • AMBO 2000
  • Country
  • GNPX United States
  • AMBO United States
  • Employees
  • GNPX N/A
  • AMBO N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • AMBO Other Consumer Services
  • Sector
  • GNPX Health Care
  • AMBO Real Estate
  • Exchange
  • GNPX Nasdaq
  • AMBO Nasdaq
  • Market Cap
  • GNPX 7.4M
  • AMBO 8.3M
  • IPO Year
  • GNPX 2018
  • AMBO 2010
  • Fundamental
  • Price
  • GNPX $0.17
  • AMBO $3.48
  • Analyst Decision
  • GNPX
  • AMBO
  • Analyst Count
  • GNPX 0
  • AMBO 0
  • Target Price
  • GNPX N/A
  • AMBO N/A
  • AVG Volume (30 Days)
  • GNPX 6.3M
  • AMBO 38.6K
  • Earning Date
  • GNPX 08-14-2025
  • AMBO 08-05-2025
  • Dividend Yield
  • GNPX N/A
  • AMBO N/A
  • EPS Growth
  • GNPX N/A
  • AMBO N/A
  • EPS
  • GNPX N/A
  • AMBO 0.69
  • Revenue
  • GNPX N/A
  • AMBO $9,699,000.00
  • Revenue This Year
  • GNPX N/A
  • AMBO N/A
  • Revenue Next Year
  • GNPX N/A
  • AMBO N/A
  • P/E Ratio
  • GNPX N/A
  • AMBO $4.88
  • Revenue Growth
  • GNPX N/A
  • AMBO 23.73
  • 52 Week Low
  • GNPX $0.14
  • AMBO $1.00
  • 52 Week High
  • GNPX $3.97
  • AMBO $5.55
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 35.07
  • AMBO 56.73
  • Support Level
  • GNPX $0.14
  • AMBO $3.35
  • Resistance Level
  • GNPX $0.25
  • AMBO $4.35
  • Average True Range (ATR)
  • GNPX 0.02
  • AMBO 0.42
  • MACD
  • GNPX -0.01
  • AMBO 0.05
  • Stochastic Oscillator
  • GNPX 23.78
  • AMBO 46.60

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.

Share on Social Networks: